期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子受体-酪氨酸激酶抑制剂联合全脑放疗同步治疗肺癌多发脑转移的研究进展 被引量：2

Advances in the research of epidermal growth factor receptor-tyrosine kinase inhibitors concomitant with whole brain radiotherapy for multiple brain metastases of lung cancer
原文传递
导出
摘要 多发脑转移是常见且严重的肺癌临床表现。全脑放疗(WBRT)为传统治疗方案。表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗脑转移灶的效果良好。本文综述TKI联合WBRT同步治疗肺癌多发脑转移的临床研究进展,分析研究现状及存在问题,为该联合治疗方案早日应用于临床提供依据。 Multiple brain metastasis of lung cancer is a common and serious clinical situation. It could be treated by whole brain radiotherapy（WBRT） as a traditional method. However, epidermal growth factor receptor-tyrosine kinase inhibitors（EGFR-TKIs） have a good effect in treating brain metastases. This review describes the clinical research progress of EGFR-TKIs combined with WBRT for the multiple brain metastases of lung cancer, analyzes present situation and problems, in order to provide basis for clinical treatment.
作者 崔少华 姜丽岩
机构地区 上海交通大学附属胸科医院呼吸内科
出处 《世界临床药物》 CAS 2015年第4期227-231,共5页 World Clinical Drug
基金 国家自然科学基金面上项目(批准号:81472175) 上海市卫生和计划生育委员会重点项目(批准号:20134007)
关键词 肺癌 多发性脑转移 全脑放疗(WBRT) 表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI) lung cancer multiple brain metastase whole brain radiotherapy（WBRT） epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）
分类号 R734.2 [医药卫生—肿瘤] R979.19 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 [J]. Clin Cancer Res, 2007, 13 (5) : 1511-1515.
  • 2Abbott N J, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrierEJ]. Neurobiol Dis, 2010, 37(1): 13-25.
  • 3Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353 (2) : 123-132.
  • 4Halatsch ME, L6w S, Mursch K, et al. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib: Laboratory investigation[J]. JNeurosurg, 2009, 111 (2): 211-218.
  • 5Zhuang HQ, Sun J, Yuan ZY, et al. Radiosensitizing effects of gefitinib at different administration times in vitro [J]. Cancer Sci, 2009, 100 (8) : 1520-1525.
  • 6Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) [J]. Cancer Res, 2005, 65 (8) : 3328-3335.
  • 7Lind JS, Lagerwaard FJ, Smit EF, et al. Phase II study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2009, 74 (5) : 1391-1396.
  • 8Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer [J]. J Clin Oncol, 2013, 31 (7) : 895-902.
  • 9Ma S, Xu Y, Deng Q, et al. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population [J]. Lung Cancer,2009, 65 (2) : 198-203.
  • 10Zeng YD, Zhang L, Liao H, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brainmetastasis from non-small-cell lung cancer: a retrospective study[J]. Asian Pac J Cancer Prey, 2012, 13 (3) : 909-914.

同被引文献15

引证文献2

二级引证文献12

世界临床药物
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部